Adaptimmune Therapeutics PLC: key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2024)
- $178.0M
- Net Income/Loss (FY2024)
- -$70.8M
- Total Assets (FY2024)
- $246.0M
- Total Equity (FY2024)
- $11.8M
- Cash Flows from Operating Activities (FY2024)
- -$73.2M
Source: Adaptimmune Therapeutics PLC 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
